LUCA Science

Executive Summary

LUCA Science is a preclinical-stage Japanese biotechnology company pioneering mitochondrial therapy through its proprietary iMIT platform, which enables isolation, storage, and delivery of functional mitochondria as biopharmaceutical agents. The company's approach aims to restore cellular bioenergetics in damaged tissues, targeting inherited mitochondrial diseases, ischemia-reperfusion injuries, and immunometabolic disorders. Founded in 2020 and based in Tokyo, LUCA Science operates in a highly innovative but early-stage space within immunology, with significant potential to address unmet medical needs in conditions where mitochondrial dysfunction plays a key role. As a private company with no disclosed funding rounds or valuation, LUCA Science's progress is early, but its novel technology could attract strategic partnerships and investment from pharmaceutical companies interested in mitochondrial therapeutics.

Upcoming Catalysts (preview)

• Q4 2026Series A or Seed Funding Announcement40% success
• Q2 2027Preclinical Proof-of-Concept Data Release for Lead Indication30% success
• 2027Collaboration or Licensing Deal with a Major Pharma25% success